Impact of CYP3A7, CYP2D6 and ABCC2/ABCC3 polymorphisms on tacrolimus steady state concentrations in Bulgarian kidney transplant recipients

References

• Provenzani A, Santeusanio A, Mathis E, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol. 2013;19(48):9156–9173.
   PubMed Web of Science ®Google Scholar
• Penninga L, Wettergren A, Chan AW, et al. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Cochrane Database Syst Rev. 2012;3:CD008852.
   Google Scholar
• Ponticelli C. Present and future of immunosuppressive therapy in kidney transplantation. Transplant Proc. 2011;43(6):2439–2440.
   PubMed Web of Science ®Google Scholar
• Picard N, Marquet M. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol. 2011;7(6):731–743.
   PubMed Web of Science ®Google Scholar
• Tang JT, Andrews LM, van Gelder T, et al. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Expert Opin Drug Metab Toxicol. 2016;12(5):555–565.
   PubMed Web of Science ®Google Scholar
• Lamba J, Hebert JM, Schuetz EG, et al. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012;22(7):555–558.
   PubMed Web of Science ®Google Scholar
• Liu H, Xu Q, Huang W, et al. CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria [published correction appears in Eur J Clin Pharmacol. 2021 Jan 30]. Eur J Clin Pharmacol. 2019;75(11):1533–1540.
   PubMed Web of Science ®Google Scholar
• Lam YWF. Pharmacogenomics. In: Lam YWF, Scott SA, editors. Principles of pharmacogenomics: pharmacokinetic, pharmacodynamic, and clinical implications. 2nd ed. London (UK): Academic Press; 2019. p. 1–53.
   Google Scholar
• Rodriguez-Antona C, Axelson M, Otter C, et al. A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. J Biol Chem. 2005;280(31):28324–28331.
   PubMed Web of Science ®Google Scholar
• Passey C, Birnbaum AK, Brundage RC, et al. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol. 2011;72(6):948–957.
   PubMed Web of Science ®Google Scholar
• Capron A, Mourad M, De Meyer M, et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics. 2010;11(5):703–714.
   PubMed Web of Science ®Google Scholar
• Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268(9):6077–6080.
   PubMed Web of Science ®Google Scholar
• Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014;10(10):1337–1354.
   PubMed Web of Science ®Google Scholar
• Shuker N, Bouamar R, Weimar W, et al. ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin Chim Acta. 2012;413(17–18):1326–1337.
   PubMed Web of Science ®Google Scholar
• Vafadari R, Bouamar R, Hesselink DA, et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther Drug Monit. 2013;35(4):459–465.
   PubMed Web of Science ®Google Scholar
• Ogasawara K, Chitnis SD, Gohh RY, et al. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013;52(9):751–762.
   PubMed Web of Science ®Google Scholar
• Zhao W, Elie V, Roussey G, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86(6):609–618.
   PubMed Web of Science ®Google Scholar
• Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007;81(2):228–234.
   PubMed Web of Science ®Google Scholar
• Genvigir FDV, Nishikawa AM, Felipe CR, et al. Influence of ABCC2, CYP2C8, and CYP2J2 polymorphisms on tacrolimus and mycophenolate sodium-based treatment in Brazilian kidney transplant recipients. Pharmacotherapy. 2017;37(5):535–545.
   PubMed Web of Science ®Google Scholar
• Filipov J, Zlatkov B, Paskalev E, et al. Relationship between vitamin D status and immunosuppressive therapy in kidney transplant recipients. Biotechnol Biotechnol Equip. 2015;29(2):331–335.
   PubMed Web of Science ®Google Scholar
• Imamura CK, Furihata K, Okamoto S, et al. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. J Clin Pharmacol. 2016;56(4):408–413.
   PubMed Web of Science ®Google Scholar
• Suetsugu K, Mori Y, Yamamoto N, et al. Impact of CYP3A5, POR, and CYP2C19 polymorphisms on trough concentration to dose ratio of tacrolimus in allogeneic hematopoietic stem cell transplantation. IJMS. 2019;20(10):2413.
   Google Scholar
• Hosohata K, Masuda S, Katsura T, et al. Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009;37(4):821–826.
   PubMed Web of Science ®Google Scholar
• Stevens JC, Hines RN, Gu C, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003;307(2):573–582.
   PubMed Web of Science ®Google Scholar
• Sim SC, Edwards RJ, Boobis AR, et al. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genom. 2005;15(9):625–631.
   PubMed Web of Science ®Google Scholar
• CYP3A7 gene. Pharmavar – pharmacogene variation consortium web site. https://www.pharmvar.org/genes. Accessed May 04, 2020.
   Google Scholar
• Sohn M, Kim MG, Han N, et al. Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients [published correction appears in Sci Rep. 2020 Feb 7;10(1):2486]. Sci Rep. 2018;8(1):18064.
   PubMedGoogle Scholar
• Sun B, Guo Y, Gao J, et al. Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients. Pharmacogenomics. 2017;18(16):1503–1513.
   PubMed Web of Science ®Google Scholar
• Burk O, Tegude H, Koch I, et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem. 2002;277(27):24280–24288.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Antona C, Jande M, Rane A, et al. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005;77(4):259–270.
   PubMed Web of Science ®Google Scholar
• Crettol S, Venetz JP, Fontana M, et al. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008;30(6):689–699.
   PubMed Web of Science ®Google Scholar
• Petrović J, Pešić V, Lauschke VM. Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe. Eur J Hum Genet. 2020;28(1):88–94.
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Dahl ML, Dalén P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53(2):111–122.
   PubMed Web of Science ®Google Scholar
• Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22(5):328–335.
   PubMed Web of Science ®Google Scholar
• Luo X, Zhu LJ, Cai NF, et al. Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin. 2016;37(4):555–560.
   PubMed Web of Science ®Google Scholar
• Shiraga T, Niwa T, Teramura Y, et al. Oxidative metabolism of tacrolimus and its metabolite by human cytochrome P450 3A subfamily. Drug Metab Pharmacokinet. 1999;14(4):277–285..
   Google Scholar
• Cascorbi I, Haenisch S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol. 2010;596:95–121.
   PubMedGoogle Scholar
• van der Schoor LW, Verkade HJ, Kuipers F, et al. New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. Expert Opin Drug Metab Toxicol. 2015;11(2):273–293.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005;20(6):452–477.
   PubMedGoogle Scholar
• König J, Rost D, Cui Y, et al. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology. 1999;29(4):1156–1163.
   PubMed Web of Science ®Google Scholar
• Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology. 2001;34(2):351–359.
   PubMed Web of Science ®Google Scholar
• Mohammad IS, He W, Yin L. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed Pharmacother. 2018;100:335–348.
   PubMed Web of Science ®Google Scholar